Furthermore, we demonstrated that patients with high allele frequency of missense and nonsense mutations in tumor specific parts had a significantly shorter relapse‐free survival time than the low mutation frequency group for the EGFR wild‐type lung cancer patients (P = 0.017, Figure 7), though no significant difference present in overall survival (P = 0.67, Figure 7). This evidence concerns the gene EGFR and lung carcinoma.